I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01177 | 說明 | - | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 30,000,000,000 | HKD | | 0.025 | HKD | | 750,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 30,000,000,000 | HKD | | 0.025 | HKD | | 750,000,000 | 本月底法定/註冊股本總額： HKD 750,000,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年3月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: ...

Core Viewpoint - The recent activities of China Biologic Products Holdings, including share buybacks and significant investments by the chairman, indicate strong confidence in the company's growth trajectory and international expansion plans [1] Group 1: Shareholder Activities - The chairman of China Biologic Products, Xie Qirun, increased his stake by acquiring 1.748 million shares at an average price of HKD 5.73, totaling an investment of HKD 10.016 million [1] - Since March 27, the company has spent over HKD 80 million on share buybacks, including the repurchase of 5.35 million shares for HKD 31.4377 million and 10 million shares for HKD 58.424 million [1] Group 2: Financial Performance - In 2025, the company reported revenue of RMB 31.83 billion, reflecting a year-on-year growth of 10.3%, and an adjusted net profit of RMB 4.54 billion, which is a 31.4% increase [1] - Revenue from new products saw a significant increase of 26.2% year-on-year, highlighting the success of the company's innovation efforts [1] Group 3: Future Outlook - Xie Qirun stated that the company has achieved double-digit growth in both revenue and net profit for four consecutive reporting periods, validating its long-term efforts in innovative drug development and strategic partnerships [1] - The year 2026 is anticipated to be a pivotal year for the company's internationalization, with recent licensing agreements marking a milestone and opening up substantial global valuation opportunities for its innovation pipeline [1]

Group 1 - The company China National Pharmaceutical Group (China Biopharmaceutical, 01177) announced a share buyback plan, intending to repurchase 10 million shares at a cost of HKD 58.424 million by March 30, 2026 [2]

Core Viewpoint - China Biopharmaceutical's adjusted net profit significantly increased by 31.4% last year, indicating strong financial performance and growth potential in the coming years [2]. Group 1: Financial Performance - The company reported a 10.3% year-on-year growth in revenue from continuing operations for 2025, aligning with earlier guidance [3]. - Revenue from innovative products grew by 26%, contributing to 48% of total revenue, showcasing the increasing importance of these products in the company's portfolio [3]. Group 2: Future Outlook - The introduction of new products such as CDK2/4/6, Zongaitin, and KRAS, which will be included in the medical insurance system, is expected to provide significant performance increments, with projected double-digit growth in product sales from 2026 to 2027 [2]. - The target price for China Biopharmaceutical has been adjusted down to HKD 7.7, while maintaining a "Buy" rating, reflecting a cautious but optimistic outlook on the company's future performance [3].

Group 1 - The core viewpoint of the report is that China Biopharmaceutical's revenue and profit for the second half of 2025 are below expectations, with a revenue growth of 10% year-on-year and a profit decline of 40% [3] - The forecast for revenue growth rates for the fiscal years 2026, 2027, and 2028 is 13%, 14%, and 12% respectively, with net profit growth rates expected to be 15% and 13% for 2027 and 2028 [2] - The main growth drivers identified are the launch of new innovative drugs and the expansion of indications for existing products, which are expected to continue to be the primary growth momentum for the company [3] Group 2 - Due to the weak performance in the second half of 2025 and the normalization of revenue contributions from commercial development, the revenue forecasts for the next two years have been revised down by 3% to 5%, and profit forecasts have been reduced by 11% to 13% [3] - The target price for China Biopharmaceutical has been lowered from HKD 9.2 to HKD 8.9, while maintaining an "outperform" rating [3]

Core Viewpoint - China Biopharmaceutical (01177) announced the acquisition of 100% equity in Hejia, with all conditions precedent for the transaction being fulfilled and the completion date set for March 30, 2026. Following the completion, Hejia will become a wholly-owned subsidiary, and its financial performance will be consolidated into the group's financial statements [1]. Group 1 - The acquisition involves the issuance of consideration shares under a general mandate [1]. - The board expressed satisfaction with the fulfillment of all conditions precedent for the transaction [1]. - Hejia's financial results will be integrated into China Biopharmaceutical's financial reports post-acquisition [1].

Group 1 - The chairman and executive director of China Biologic Products Holdings (01177) increased his shareholding by 1.748 million shares at a price of HKD 5.73 per share, totaling approximately HKD 10.016 million [1] - Following the purchase, the total number of shares held by the chairman is approximately 7.748 million, representing a holding percentage of 0.04% [1]

Core Viewpoint - The company is expected to achieve strong profit growth in 2026, driven by its leading commercialization capabilities in mainland China and a robust pipeline of new products and biosimilars, alongside an accelerated global expansion strategy [1][2] Group 1: Financial Performance - In 2025, the company's continuing operations revenue grew by 10.3% year-on-year, aligning with previous guidance [1] - Revenue from innovative products increased by 26%, contributing 48% to total revenue, primarily driven by key new products such as PD-L1, long-acting white blood cell enhancers, Bevacizumab, Trastuzumab, Pertuzumab, and seven-factor products [1] - The oncology and liver disease/cardiovascular metabolism sectors recorded revenue growth of 23% and 19%, respectively, due to rapid iteration of new products [1] - Adjusted net profit saw a significant increase of 31.4% due to improvements in gross margin and operating expense ratios [1] Group 2: Product Pipeline and Innovation - The company anticipates nearly 20 new products/new indications to be approved between 2026 and 2028, with over 40 new products expected by 2028, including potential first-in-class CLDN18.2 ADC and best-in-class CD3/EpCAM bispecific antibodies [2] - Recent acquisitions of Lixin and Hejiya are expected to rapidly support the company's pipeline iteration, with multiple single/double antibodies, ADCs, and small nucleic acid drugs expected to yield proof of concept or Phase I data in 2026 [2] - The company is evolving from a local new drug development and commercialization entity into a global comprehensive pharmaceutical innovation platform through open innovation ecosystems, including external licensing, acquisitions, and strategic collaborations [2] Group 3: Valuation and Target Price - The target price has been adjusted downward based on the 2025 performance, reflecting a more cautious outlook on BD collaboration revenue recognition and existing generic drug income [2] - The DCF target price is set at HKD 7.7, corresponding to 36 times/1.1 times the 2026 price-to-earnings ratio/PEG based on core profits, while maintaining a buy rating [2]

Core Viewpoint - China Biopharmaceutical reported a 10.3% year-on-year revenue growth to 31.83 billion yuan in 2025, with innovative product revenue increasing by 26.2% to 1.52 billion yuan, accounting for 47.8% of total revenue [1] Group 1: Financial Performance - The adjusted net profit attributable to shareholders grew by 31.4% year-on-year to 4.54 billion yuan, and even excluding the dividend from Sinovac Biotech, the adjusted net profit still increased by 15% [1] - The company's 2025 revenue was 7.4% lower than the analysts' expectations and 3.9% lower than Bloomberg consensus, while the adjusted net profit fell short by 27.5% and 9.0% respectively, primarily due to the milestone payment of 300 million USD from Merck not being accounted for as expected [1] Group 2: Innovation and Product Pipeline - In 2025, the company achieved approvals for four innovative products, including the world's first CDK2/4/6 inhibitor, Kimosir, and the first high-selectivity HER2 TKI, Zongaitini [2] - The company has a large pipeline of innovative drugs, with 39 in clinical stages in the oncology field, including several assets with global first-in-class or best-in-class potential [2] - The management aims to obtain approvals for nearly 20 innovative products and new indications between 2026 and 2028 [2] Group 3: Strategic Collaborations and Acquisitions - In February 2026, the company entered a global exclusive licensing agreement with Sanofi for 135 million USD upfront, along with milestone payments and sales royalties for the global development and commercialization rights of Roflumilast [3] - The company completed two significant acquisitions: a full acquisition of Lixin Pharmaceutical for up to 950 million USD in July 2025 and a 1.2 billion yuan acquisition of Hejiya in January 2026 [3] - The management indicated that external licensing will be a core objective for future business development, with expectations for continued successful licensing agreements [3] Group 4: Future Outlook - The company is set to disclose multiple important clinical data in 2026, including Phase I data for various innovative treatments at major conferences [3] - The target price based on DCF has been adjusted from 9.40 HKD to 8.70 HKD, reflecting a downward revision in expectations for non-business development revenue [4] - Revenue growth projections for 2026E/27E/28E are 13.5%/7.1%/9.2%, with adjusted net profit growth of 5.4%/8.3%/10.5% [4]

Core Viewpoints - China Biopharmaceutical reported a total revenue of 31.83 billion yuan for the year 2025, representing a year-on-year growth of 10.3% [1][2] - Adjusted net profit attributable to shareholders reached 4.541 billion yuan, a significant increase of 31.4% year-on-year; core net profit growth reached 15% when excluding factors like the Sinovac dividend [1][2] - The company’s innovative business showed strong performance, with revenue from innovative products growing by 26.2% year-on-year [1][2] - The internationalization strategy yielded significant results, highlighted by a $1.53 billion exclusive licensing agreement for the global FIC drug Rovaxitinib with Sanofi, marking the largest transaction in China's transplant field [1] Financial Performance - The company achieved a total revenue of 31.83 billion yuan in 2025, with a 10.3% increase compared to the previous year [1][2] - The adjusted net profit attributable to shareholders was 4.541 billion yuan, reflecting a 31.4% year-on-year growth [1][2] - The core product sales continued to grow, contributing to a robust financial position with ample cash reserves [1] Innovation and Product Development - The innovative business became the core growth engine, with innovative product revenue increasing by 26.2% year-on-year [2] - Anlotinib, a key product, benefited from the approval of three new first-line indications in 2025, leading to significant sales growth [2] - The company is focusing on several key clinical data releases in 2026, including results for LM-302 in first-line gastric cancer and TQB6411 in late-stage malignancies [8] Research and Development - The company is accelerating clinical progress in oncology, with multiple products showing FIC/BIC potential [3][4] - The small RNA business is developing a long-acting siRNA pipeline, with Kylo-11 showing significant potential in the cardiovascular field [4][5] - The company has established a comprehensive small RNA technology platform, laying the foundation for future product development and commercialization [5] Future Outlook - The company expects to achieve revenues of 35.782 billion yuan, 40.899 billion yuan, and 47.075 billion yuan from 2026 to 2028, with corresponding net profits of 3.591 billion yuan, 4.164 billion yuan, and 4.808 billion yuan [9] - The company maintains a "buy" rating based on its growth prospects and expected financial performance [9]